Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Complications of atherosclerosis are the most common cause of death in Western societies. Among the many risk factors identified by epidemiological studies, only elevated levels of lipoproteins containing apolipoprotein (apo) B can drive the development of atherosclerosis in humans and experimental animals even in the absence of other risk factors. However, the mechanisms that lead to atherosclerosis are still poorly understood. We tested the hypothesis that the subendothelial retention of atherogenic apoB-containing lipoproteins is the initiating event in atherogenesis. The extracellular matrix of the subendothelium, particularly proteoglycans, is thought to play a major role in the retention of atherogenic lipoproteins. The interaction between atherogenic lipoproteins and proteoglycans involves an ionic interaction between basic amino acids in apoB100 and negatively charged sulphate groups on the proteoglycans. Here we present direct experimental evidence that the atherogenicity of apoB-containing low-density lipoproteins (LDL) is linked to their affinity for artery wall proteoglycans. Mice expressing proteoglycan-binding-defective LDL developed significantly less atherosclerosis than mice expressing wild-type control LDL. We conclude that subendothelial retention of apoB100-containing lipoprotein is an early step in atherogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated concentration of low-density lipoprotein enhances its retention under the arterial wall(17); retention and oxidation of low-density lipoprotein are fundamental events in atherogenesis.(18)”
From Endometriosis and Risk of Coronary Heart Disease (2016) · cites this paper as [18]
In the citing paper
“The ECM has a central role in initiation of atherosclerosis, primarily through the interaction between the negatively charged side chains of proteoglycans (particularly chondroitin sulphate of biglycan and versican and heparin sulphate of perlecan 110 ) with positively charged apolipoproteins (especially apolipoprotein B) , which leads to the retention of plasma-derived lipoproteins 101,111 - as”
From Vascular smooth muscle cells in atherosclerosis (2019) · cites this paper as [101]
In the citing paper
“the interaction of apoB-containing lipoproteins (the non-HDL lipoproteins) with intimal extracellular proteoglycans (referred to as retention)1,43,44 inhibits the movement of the lipoproteins, thereby resulting in much higher subendothelial concentrations of these lipoproteins in the intima than in any other tissue45.”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [44]
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
Efficient Trace-labelling of Proteins with Iodine
McFARLANE, A. S. (1958) · Nature · doi:10.1038/182053a0 · Cited by 2,543
A simple fluorometric assay for lipoperoxide in blood plasma
Yagi, K. (1976) · Biochemical Medicine · doi:10.1016/0006-2944(76)90049-1 · Cited by 2,103 · cited 1×
“The concentrations of thiobarbituric-acid-reactive substance”
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Cell Biology of Atherosclerosis
Ross, R. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.004043 · Cited by 1,003 · cited 1×
“gif" NDATA ITEM> ]> Complications of atherosclerosis are the most common cause of death in Western societie”
BackgroundTangirala, R. K., Rubin, E. M., & Palinski, W. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39713-3 · Cited by 514
Mahley, R. W., Innerarity, T. L., Pitas, R. E., Weisgraber, K. H., Brown, J. H., & Gross, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)66966-8 · Cited by 383
Self-citationBorén, J., Olin, K., Lee, I., Chait, A., Wight, T. N., & Innerarity, T. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2265 · Cited by 320 · cited 1×
“The interaction between atherogenic lipoproteins and proteoglycans involves an ionic interaction between basic amino acids in apoB100 and negatively charged sulphate groups on the proteoglycan”
BackgroundSelf-citationImmunoglobulin treatment reduces atherosclerosis in apo E knockout mice.
Nicoletti, A., Kaveri, S., Caligiuri, G., Bariéty, J., & Hansson, G. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119892 · Cited by 301
Cited by
Items 501–600 of 1,000
Robinson, G., Pineda‐Torra, I., Ciurtin, C., & Jury, E. C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.914016 · Cited by 24
“Importantly, increased circulating concentrations of LDL and VLDL in plasma have been shown to induce the development of atherosclerosis, independent of other risk factors (35).”
BackgroundWang, R., Xu, J. H., Tang, Y., Wang, Y., Zhao, J., Ding, L., Peng, Y., & Zhang, Z. (2023) · Scientific Reports · doi:10.1038/s41598-022-26556-6 · Cited by 18
Qu, C., Li, X., & Gao, H. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2405153 · Cited by 19
“The infiltration of low-density lipoprotein (LDL) in the arterial wall initiated the inflammatory response [13].”
BackgroundTeixeira, L. D. S., Grasso, A., Monteiro, A. M., Neto, A. M. F., Vieira, N. D., Gidlund, M., & Courrol, L. C. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.01.030 · Cited by 18
“Studies have demonstrated that the LDL retention in the extracellular matrix of the arterial wall triggers a cascade the pro-atherogenic events, such as LDL oxidation [3,4].”
BackgroundWeiss, R., Spittler, A., Schmitz, G., Fischer, M. B., & Weber, V. (2014) · Biomacromolecules · doi:10.1021/bm500492r · Cited by 18
Feasibility of in vivo 18F-florbetaben PET/MR imaging of human carotid amyloid-β
Bucerius, J. A., Barthel, H., Tiepolt, S., Werner, P., Sluimer, J. C., Wildberger, J. E., Patt, M., Hesse, S., Gertz, H., Biessen, E. A. L., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3651-2 · Cited by 20
A study on the risk factors of coronary artery disease in patients with Takayasu arteritis
Wang, Y., Jia, S., Zhou, Y., Li, J., Zhao, X., Zhao, Q., & Yang, G.-L. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-267 · Cited by 18
“The effects of glucocorticoid therapy on the lipid spectrum mainly include VLDL, TG, and LDL-C, while HDL-C can be increased or decreased, while the increase of serum cholesterol (mainly LDL-C) is positively correlated with the occurrence of atherosclerosis (20).”
BackgroundMitochondrial Contact Sites in Inflammation-Induced Cardiovascular Disease
Liu, H., Liu, X., Zhuang, H., Fan, H., Zhu, D., Xu, Y., He, P., Liu, J., & Feng, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00692 · Cited by 21
“In hypercholesteremia, cholesterol-carrying LDL particles remain in the arterial wall (Williams and Tabas, 1995; Skalen et al., 2002; Hansson, 2005).”
BackgroundMéndez‐Lara, K. A., Letelier, N. A., Farré, N., Diarte‐Añazco, E. M. G., Nieto‐Nicolau, N., Rodríguez‐Millán, E., Santos, D., Pallarès, V., Escolá‐Gil, J. C., del Olmo, T. V., et al. (2020) · Antioxidants · doi:10.3390/antiox9111162 · Cited by 19
Adiponectin inhibits the binding of low-density lipoprotein to biglycan, a vascular proteoglycan
Kobayashi, K., Inoguchi, T., Sonoda, N., Sekiguchi, N., & Nawata, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.048 · Cited by 19
Hagensen, M. K., Mortensen, M. B., Kjølby, M., Palmfeldt, J., Bentzon, J. F., & Gregersen, S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.027 · Cited by 18
Leng, Y., Zhang, Y., Li, X., Wang, Z., Zhuang, Q., & Lu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.762334 · Cited by 19
Otto, S., Lütjohann, D., Kerksiek, A., Friedrichs, S., Schulze, P. C., Möbius‐Winkler, S., Pörner, T. C., & Weingärtner, O. (2022) · Steroids · doi:10.1016/j.steroids.2022.109079 · Cited by 17
Ubiquitous regulation of cerebrovascular diseases by ubiquitin‐modifying enzymes
Huang, J., Zhu, Z., Schlüter, D., Lambertsen, K. L., Song, W., & Wang, X. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1719 · Cited by 21
“The atherosclerotic process begins with the accumulation of LDLs in the sub-endothelial space of arteries 127 (Figure 4A).”
BackgroundWeiss, R., Eichhorn, T., Spittler, A., Mičušík, M., Fischer, M. B., & Weber, V. (2015) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33588 · Cited by 17
Imaging of coronary atherosclerosis in various susceptible groups
Munnur, R. K., Nerlekar, N., & Wong, D. T. L. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2016.03.02 · Cited by 21
“Binding of low density lipoproteincholesterol (LDL-C) to intimal proteoglycans is an important initial step (5) followed by LDL modification by oxidation and aggregation resulting in foam cells (6).”
BackgroundChang, C., Lin, X.-R., Lin, Y.-L., Fang, W.-H., Lin, S., Chang, S., & Kao, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192740 · Cited by 17
Hsu, W., Lai, C.-W., Chen, S., Chiou, H.-Y. C., Hsiao, P., Shin, S., & Lee, M. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0002 · Cited by 18
Zhao, Q., Jiang, Y., Zhang, M., Chu, Y., Ji, B., Pan, H., & Ban, B. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1062-z · Cited by 20
From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis
D’Ardes, D., Santilli, F., Guagnano, M. T., Bucci, M., & Cipollone, F. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00356-y · Cited by 18
Accelerated miniature swine models of advanced atherosclerosis: A review based on morphology
Wang, D., Xu, X., Zhao, M., & Wang, X. (2020) · Cardiovascular Pathology · doi:10.1016/j.carpath.2020.107241 · Cited by 23
ROS-Based Nanoparticles for Atherosclerosis Treatment
Hu, X., Zhao, P., Lu, Y., & Liu, Y. (2021) · Materials · doi:10.3390/ma14226921 · Cited by 17
“At present, oxidative stress is considered the main mechanism of AS, and it is widely believed that oxidative stress is an imbalance between the antioxidant capacity and activity species [10,11].”
BackgroundOpinion: On the Way towards the New Paradigm of Atherosclerosis
Aa, M., & Beznoussenko, G. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042152 · Cited by 17
“The atherogenicity of LDL is linked to the ability of its apoB100 moiety to interact with arterial wall proteoglycans [11,125].”
BackgroundThe Spectrum of B Cell Functions in Atherosclerotic Cardiovascular Disease
Smeets, D., Gisterå, A., Malin, S., & Tsiantoulas, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.864602 · Cited by 19
“Atherosclerosis is a lipid-driven chronic inflammatory disease characterized by progressive retention of cholesterolcarrying low-density lipoprotein (LDL) particles in the subendothelial space of arteries (6, 7) followed by a chronic maladaptive immune response (4, 8–12) and remodeling of the artery wall (13), fueled…”
BackgroundHuman macrophages limit oxidation products in low density lipoprotein
Hultén, L. M., Ullström, C., Krettek, A., van Reyk, D. M., Marklund, S. L., Dahlgren, C., & Wiklund, O. (2005) · Lipids in Health and Disease · doi:10.1186/1476-511x-4-6 · Cited by 22
“In light of the response-to-retention hypothesis of atherosclerosis, subendothelial retention of atherogenic LDL is the initiating event of the disease [39,40].”
Self-citationTargeting abdominal obesity in cardiology: Can we be effective?
Poirier, P. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)71044-4 · Cited by 17
“The atherosclerotic process begins at a very young age (five to 10 years) (27,28), and it was reported in an autopsy study that the extent of fatty streaks and even advanced lesions (fibrous plaques and plaques with calcification or ulceration) in the right coronary artery and abdominal aorta were associated with obes…”
BackgroundGrönberg, C., Bengtsson, E., Fredrikson, G. N., Nitulescu, M., Asciutto, G., Persson, A. F., Andersson, L. I. M., Nilsson, J. Å., Gonçalves, I., & Björkbacka, H. (2015) · Stroke · doi:10.1161/strokeaha.115.009910 · Cited by 19
“The entrapment and modification of low-density lipoprotein particles trigger inflammatory events in the vessel wall, which occur early in the atherosclerotic plaque formation.(2) Advanced rupture-prone (vulnerable) atherosclerotic plaques are characterized by large extracellular lipid deposits, necrosis, and reduced c…”
BackgroundObésité et maladies cardiovasculaires
Poirier, P., & Després, J. (2003) · médecine/sciences · doi:10.1051/medsci/20031910943 · Cited by 39
Williams, K. J., Tabas, I. A., & Fisher, E. A. A. (2015) · Circulation Research · doi:10.1161/circresaha.115.307609 · Cited by 18
Pathological phenotypes of LDL particles
Laufs, U., & Weingärtner, O. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy387 · Cited by 17
Rodriguez‐Duarte, J., Galliussi, G., Dapueto, R., Rossello, J., Malacrida, L. S., Kamaid, A., Schopfer, F. J., Escande, C., López, G. V., & Batthyány, C. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14561 · Cited by 17
“At the atherosclerotic lesion site in conduit arteries, there is an increased retention of LDL and other lipoproteins particles in the intima layer of the artery wall, which is facilitated by alterations induced by the inflammatory response (endothelial dysfunction) and pro-atherogenic modifications of the LDL particl…”
BackgroundKumarapperuma, H., Chia, Z.-J., Malapitan, S. M., Wight, T. N., Little, P. J., & Kamato, D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118552 · Cited by 21
Kristo, A. S., Malavaki, C. J., Lamari, F. N., Karamanos, N. K., & Klimis‐Zacas, D. J. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.05.002 · Cited by 18
“Subendothelial retention of apoB100 lipoprotein, the major apolipoprotein of human LDL, is an early step in atherogenesis, with the atherogenicity of the LDL particle linked to its binding affinity for arterial PGs [19,38].”
BackgroundLittle, P. J., Drennon, K., & Tannock, L. R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802033909 · Cited by 16
“ISSN 1381-3455 print/ISSN 1744-4160 online ª 2008 Informa UK Ltd. DOI: 10.1080/13813450802033909 1998; Nakashima et al., 2007; Skalen et al., 2002; Ballinger et al., 2004).”
InfluentialOlkowicz, M., Czyżyńska-Cichoń, I., Szupryczyńska, N., Kostogrys, R. B., Kochan, Z., Dȩbski, J., Dadlez, M., Chłopicki, S., & Smolenski, R. T. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02663-8 · Cited by 19
Grijalva-Guiza, R. E., Jiménez-Garduño, A. M., & Hernández, L. R. (2021) · Molecules · doi:10.3390/molecules26123557 · Cited by 17
“During this process, it has been demonstrated that negatively charged side chains of proteoglycans interact with the positively charged side of apolipoproteins [48] to retain lipoproteins from plasma [30].”
BackgroundSleep Fragmentation and Atherosclerosis: is There a Relationship?
Bhagavan, S., & Sahota, P. K. (2021) · Missouri medicine · Cited by 24
Dunér, P., Gonçalves, I., Grufman, H., Edsfeldt, A., To, F., Nitulescu, M., Nilsson, J. Å., & Bengtsson, E. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.043 · Cited by 18
“[4].”
Regulation of Vascular Proteoglycan Synthesis by Metabolic Factors Associated with Diabetes
Wilson, P. G., Drennon, K., & Tannock, L. R. (2007) · Journal of Investigative Medicine · doi:10.2310/6650.2007.05067 · Cited by 17
O’Keefe, J. H., DiNicolantonio, J. J., & Lavie, C. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.11.001 · Cited by 17
“LDL-C penetrates the intima whereby Apo B binds to proteoglycans leading to oxidized LDL-C, which incites inflammation, endothelial dysfunction, and atherosclerosis.(7) Severe elevations of LDL-C levels (> 190 mg/dL) are strongly associated with CHD risk; however atherosclerosis and its complications are common even f…”
BackgroundMolecular Basis of Obesity and the Risk for Cardiovascular Disease
Soufi, M., Sattler, A., Herzum, M., Maisch, B., & Schaefer, J. R. (2006) · Herz · doi:10.1007/s00059-006-2801-2 · Cited by 16
“The retention within the intima enhances oxidative processes and accumulation of foam cells [58].”
BackgroundIncreasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease
Badimón, J. J., & Ibáñez, B. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70065-7 · Cited by 20
“After the foam-macrophage cells die, the cholesterol is again released into the arterial wall forming the lipid core of the plaque, thus perpetuating the process.(9) Furthermore, cholesterol can crystallize, and this has recently been identified as a factor in the destabilization of plaque.”
BackgroundProgression to Cirrhosis Leads to Improvement in Atherogenic Milieu
Patel, S. S., Siddiqui, M. B., Chandrakumaran, A., Rodríguez, V., Faridnia, M., Roman, J. H., Zhang, E. D., Patrone, M. V., Kakiyama, G., Walker, C. H., et al. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06196-4 · Cited by 17
Li, W., Yu, J., Xiao, X., Zang, L., Yang, Y., Yu, J., Huang, Q., Niu, X., & Li, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107170 · Cited by 16
Radkhah, N., Shab‐Bidar, S., Zarezadeh, M., Safaeiyan, A., & Barzegar, A. (2021) · Journal of Cardiovascular and Thoracic Research · doi:10.34172/jcvtr.2021.21 · Cited by 15
Vaccines in Development to Prevent and Treat Atherosclerotic Disease
Riley, E., Dasari, V. M., Frishman, W. H., & Sperber, K. E. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e3181885933 · Cited by 15
“For example, a human HSP may cross react with mycobacterial HSP65 and chlamydial HSP60.(34) This may explain why certain infections are linked to atherosclerosis.”
BackgroundInfluentialNuclear Molecular Imaging for Vulnerable Atherosclerotic Plaques
Lee, S. J., & Paeng, J. C. (2015) · Korean Journal of Radiology · doi:10.3348/kjr.2015.16.5.955 · Cited by 18
“LDL may exhibit spontaneous involution; however, LDL is prone to oxidation when it is isolated from circulating antioxidants (6, 7).”
BackgroundHanda, J. T., Tagami, M., Ebrahimi, K. B., Leibundgut, G., Janiak, A., Witztum, J. L., & Tsimikas, S. (2015) · Europe PMC (PubMed Central) · Cited by 21
Reduction of Heat Shock Protein Antibody Levels by Statin Therapy
Guisasola, M. C., Dulín, E., Almendral, J. M., & Garcia-Barreno, P. (2008) · Lipids · doi:10.1007/s11745-008-3265-3 · Cited by 15
“LDL infiltration and retention in the arterial intima starts an inflammatory response in the arterial wall [3].”
BackgroundNovel Imaging Techniques for Quantifying Overall Atherosclerotic Burden
Ibáñez, B., Pinero, A., Orejas, M., & Badimón, J. J. (2007) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(07)60154-6 · Cited by 18
“Following the death of the macrophage foam cells, the cholesterol is again released into the arterial wall, thus perpetuating the process.(6,7) Finally, the cholesterol can crystallize, a factor that has recently been reported to destabilize the plaque.”
BackgroundRole of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis
Udachkina, E. V., Novikova, D. S., Попкова, Т. В., & Nasonov, E. L. (2013) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2013-7 · Cited by 19
Caveolin-1-mediated LDL transcytosis across endothelial cells in atherosclerosis
Zhang, Y., Jia, X., Wang, Y., & Zheng, Q. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119113 · Cited by 16
Biosensors for detection of Low-Density Lipoprotein and its modified forms
Andrade, C. A. S., Danielly, M., Faulin, T. D. E. S., Hering, V. R., & Abdalla, D. S. P. (2011) · InTech eBooks · doi:10.5772/19938 · Cited by 16
“The entrapment of LDL in the arterial intima is mainly due to the specific interaction between the lysine-rich sites on apoB100 and the extracellular matrix (ECM) components such as collagen, proteoglycans (PGs), and glycosaminoglycans (GAGs) (D’Ulivo et al., 2010).”
BackgroundCilpa-Karhu, G., Lipponen, K., Samuelsson, J., Öörni, K., Fornstedt, T., & Riekkola, M. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.09.014 · Cited by 14
Mittal, R., Jhaveri, V. M., Kay, S.-I. S., Greer, A. B., Sutherland, K. J., McMurry, H. S., Lin, N., Mittal, J., Malhotra, A. K., & Patel, A. P. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180508111353 · Cited by 17
Ohukainen, P., Kuusisto, S. M., Kettunen, J., Perola, M., Järvelin, M., Mäkinen, V., & Ala‐Korpela, M. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.009 · Cited by 17
Acid-sensing ion channels: Linking extracellular acidification with atherosclerosis
Zhang, R.-J., Yin, Y., Xie, X., & Gu, H. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.027 · Cited by 15
Jayaraman, S., Chavez, O. R., Pérez, A., Miñambres, I., Sánchez‐Quesada, J. L., & Gursky, O. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158712 · Cited by 16
“These interactions are driven by Coulombic attraction of sulfates and carboxylates from HSPG (or its mimetics such as heparin) to lysine- and arginine-rich segments of the major LDL protein, apolipoprotein B (apoB) ([2, 3, 8] and references therein), as well as minor LDL proteins, apoE, apoJ and apoC-III [9–12].”
BackgroundEpigenetic control of atherosclerosis via DNA methylation: A new therapeutic target?
Gorabi, A. M., Penson, P. E., Banach, M., Motallebnezhad, M., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117682 · Cited by 14
Guo, L. N., & Nambudiri, V. E. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05257-3 · Cited by 14
GlycA for long-term outcome in T2DM secondary prevention
Zierfuss, B., Höbaus, C., Herz, C. T., Pesau, G., Mrak, D., Koppensteiner, R., & Schernthaner, G.-H. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108583 · Cited by 16
Biglycan expression and its function in human ligamentum flavum
Salimi, H., Suzuki, A., Habibi, H., Orita, K., Hori, Y., Yabu, A., Terai, H., Tamai, K., & Nakamura, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-84363-x · Cited by 14
Ma, S., Xia, M., & Gao, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.681444 · Cited by 17
“Circulating LDLs penetrate endothelial cells and enter the intimal space, especially in the context of hypercholesterolemia (93, 94).”
BackgroundWitos, J., Saint‐Guirons, J., Meinander, K., D’Ulivo, L., & Riekkola, M. (2011) · The Analyst · doi:10.1039/c1an15156h · Cited by 14
The role of lectin-like oxidised low-density lipoprotein receptor-1 in vascular pathology
Shaw, D. J., Seese, R., Ponnambalam, S., & Ajjan, R. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114547704 · Cited by 16
Zhang, Y., Ping, G., Kaji, N., Tokeshi, M., & Baba, Y. (2007) · Electrophoresis · doi:10.1002/elps.200700088 · Cited by 16
Effect of Dehydroepiandrosterone on Atherosclerosis in Apolipoprotein E-Deficient Mice
Yamakawa, T., OGIHARA, K., Nakamura, M., Utsunomiya, H., Kadonosono, K., Kishikawa, S., & Terauchi, Y. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.no618 · Cited by 15
Human low density lipoprotein: the mystery of core lipid packing
Prassl, R. (2010) · Journal of Lipid Research · doi:10.1194/jlr.e013417 · Cited by 14
Kjeldsen, E. W., Thomassen, J. Q., Rasmussen, K. L., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796022000567 · Cited by 13
Lysosome Functions in Atherosclerosis: A Potential Therapeutic Target
Wang, Z., Li, X., Moura, A. K., Hu, J. Z., Wang, Y., & Zhang, Y. (2025) · Cells · doi:10.3390/cells14030183 · Cited by 18
Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393333 · Cited by 18
Witos, J., Samuelsson, J., Cilpa-Karhu, G., Metso, J., Jauhiainen, M., & Riekkola, M. (2015) · The Analyst · doi:10.1039/c5an00210a · Cited by 13
Han, S. J., Fujimoto, W. Y., Kahn, S. E., Leonetti, D. L., & Boyko, E. J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.351 · Cited by 15
“Research has demonstrated that direct interaction between apoB and proteoglycans in the subendothelial space initiates an early stage of atherosclerosis [31].”
BackgroundLightbody, R. J., Taylor, J. M. W., Dempsie, Y., & Graham, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159005 · Cited by 15
High-density lipoprotein: A fall from grace?
van Leuven, S. I., Stroes, E. S. G., & Kastelein, J. J. P. (2008) · Annals of Medicine · doi:10.1080/07853890802082104 · Cited by 13
“Atherosclerosis is a chronic inflammatory disorder which is thought to originate from subendothelial retention of apoB-containing lipoproteins (8).”
BackgroundMechanistic roles of lipoprotein lipase and sphingomyelinase in low density lipoprotein aggregation
Walters, M., & Wrenn, S. P. (2011) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2011.07.072 · Cited by 16
Papaioannou, I., Simons, J. P., & Owen, J. S. (2012) · Cardiology Research and Practice · doi:10.1155/2012/148796 · Cited by 20
“Induction of smooth muscle cell migration and proliferation by oxidized LDL or platelet-derived growth factor are also suppressed by ApoE [49], while subendothelial retention of LDL, an early proatherogenic event [50], is impeded by the presence of ApoE, which additionally regulates the availability of cytokines and g…”
BackgroundJguirim-Souissi, I., Billiet, L., Cuaz‐Pérolin, C., Michaud, N., & Rouis, M. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.020 · Cited by 15
Dabigatran etexilate and reduction in serum apolipoprotein B
Joseph, P. G., Paré, G., Wallentin, L. C., Connolly, S. J., Yusuf, S., Wang, J., Ezekowitz, M. D., Eikelboom, J. W., Siegbahn, A. G., Reilly, P. A., et al. (2015) · Heart · doi:10.1136/heartjnl-2015-307586 · Cited by 14
“14 – 17 A higher atherosclerotic lipid burden, characterised by an elevated ApoB or ApoB/ApoA1 ratio, has been consistently associated with increasing cardiovascular disease risk, and both primary and secondary cardiovascular disease prevention studies have demonstrated that lowering atherogenic…”
Underlying Genes Involved in Atherosclerotic Macrophages: Insights from Microarray Data Mining
Wang, W., Zhang, K., Zhang, H., Li, M., Zhao, Y., Wang, B., Xin, W., Yang, W., Zhang, J., Yue, S., et al. (2019) · Medical Science Monitor · doi:10.12659/msm.917068 · Cited by 13
“The main features of atherosclerotic lesions are that they contain subintimal lipid deposition in certain parts of the arteries, and they have the abnormal proliferation of smooth muscle cells or fibrous matrix components [1,2].”
BackgroundCEC: A tool for mimicking collagen–surface interactions with apolipoprotein B‐100 peptides
D’Ulivo, L., Witos, J., Öörni, K., Kovanen, P. T., & Riekkola, M. (2009) · Electrophoresis · doi:10.1002/elps.200900245 · Cited by 13
Risk factors for cardiovascular events and incident hospital-treated diabetes in the population
Khalili, P. (2012) · Örebro University Library (Örebro University) · Cited by 32
Borén, J., Packard, C. J., Nordestgaard, B. G., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf214 · Cited by 12
Self-citationOberkersch, R. E., Maccari, F., Bravo, A., Volpi, N., Gazzaniga, S., & Calabrese, G. C. (2014) · International Journal of Experimental Pathology · doi:10.1111/iep.12072 · Cited by 12
“The first hypothesis is the response-to-retention hypothesis, which emphasizes that the interaction between ECM mole- cules, particularly proteoglycans (PGs) and lipoproteins, is the key event in early atherogenesis (Williams & Tabas 1995; Camejo et al. 1998; Skalen et al. 2002).”
BackgroundKang, K., Wang, Y., Wu, J., Wang, A., Zhang, J., Xu, J., Ju, Y., & Zhao, X. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.555274 · Cited by 12
Lewis, E. A., Muñiz-Anquela, R., Redondo‐Angulo, I., González-Cintado, L., Labrador-Cantarero, V., & Bentzon, J. F. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318573 · Cited by 12
PPARα: its role in the human metabolic syndrome
Azhar, S., & Kelley, G. (2007) · Future Lipidology · doi:10.2217/17460875.2.1.31 · Cited by 14
“In atherosclerosis, macrophages take up atherogenic oxidized LDL [206], resulting in their transformation into lipid-loaded macrophages or foam cells (Figure 5).”
BackgroundLipoprotein glycation in atherogenesis
Younis, N. N., Soran, H., Sharma, R., Charlton-Menys, V., & Durrington, P. N. (2009) · Clinical Lipidology · doi:10.2217/clp.09.61 · Cited by 18
Guha, M., & Gursky, O. (2011) · Journal of Lipids · doi:10.1155/2011/493720 · Cited by 13
p38 MAP Kinase Mediated Proteoglycan Synthesis as a Target for the Prevention of Atherosclerosis
Osman, N., Ballinger, M. L., Dadlani, H., Getachew, R., Burch, M. L., & Little, P. J. (2008) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152908786786205 · Cited by 14
“(positively charged amino acid residues mutated to negative or neutral) where those that do not bind to proteoglycans do not precipitate atherosclerosis [16, 47].”
Weiss, R., Fischer, M. B., & Weber, V. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21519 · Cited by 13
Cholesterol: A Prelate in Cell Nucleus and its Serendipity
Saxena, N., & Chandra, N. C. (2020) · Current Molecular Medicine · doi:10.2174/1566524020666200413112030 · Cited by 12
Prassl, R., & Laggner, P. (2012) · InTech eBooks · doi:10.5772/48145 · Cited by 14
“characteristics determine the fate of LDL in the subendothelial space [8,9].”
BackgroundSarduy, R., Brito, V., Castillo, A., Soto, Y., Griñán, T., Marleau, S., & Vázquez, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00232 · Cited by 12
“org March 2017 | Volume 8 | Article 232 This retention occurs by electrostatic interactions between glycosaminoglycan (GAG) chains and basic residues present in apoB-containing lipoproteins (6, 7).”
BackgroundEnzymatically modified LDL atherosclerosis and beyond paving the way to acceptance
Torzewski, M. (2017) · Frontiers in bioscience · doi:10.2741/4642 · Cited by 12
“1258 © 1996-2018 modification of the lipoprotein occurring prior to insudation is highlighted by the demonstration that transgenic mice expressing modified apolipoprotein B that binds poorly to proteoglycans show reduced atheroma development (7).”
BackgroundInhibition of the Synthesis of Apolipoprotein B-Containing Lipoproteins
Greeve, J. C. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-27661-0_18 · Cited by 14
Weaving Klotho into bile acid metabolism
Moschetta, A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26046 · Cited by 12
Neuro-immune axis in atherosclerosis: mechanisms of regulation and therapeutic opportunities
Shang, Y., Pan, Y., Xie, L., Zhao, Y. G., Mao, W., & Chen, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619338 · Cited by 11
Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications
Triglia, L. T., Gurgoglione, F. L., Barocelli, F., Bianconcini, M., & Niccoli, G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673311105240902053715 · Cited by 12
Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia
Crooke, R. M., & Graham, M. J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.59 · Cited by 11
Metadata
- Authors
- Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J.
- Affiliations
- University of Gothenburg (SE)
- Gladstone Institutes (US)
- Corresponding author
- Borén, Jan
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6890
- Pages
- 750-754
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083154566
- Cited by
- 1,019
- References
- 28
- Citations by year
- 2026: 23 · 2025: 28 · 2024: 38 · 2023: 42 · 2022: 41 · 2021: 69 · 2020: 48 · 2019: 39 · 2018: 39 · 2017: 29 · 2016: 27 · 2015: 46 · 2014: 42 · 2013: 42 · 2012: 63
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- American Heart Association
- Research to Prevent Blindness
- Vetenskapsrådet
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- atherosclerosis, atherogenesis, apolipoprotein B, apolipoprotein B-100, low-density lipoprotein, proteoglycans, extracellular matrix, sulfate groups, transgenic mice, atherogenic lipoproteins
- MeSH terms
- Animals, Aorta, Apolipoproteins B, Arteriosclerosis, Binding, Competitive, Cholesterol, Diet, Atherogenic, Endothelium, Vascular, Female, Humans, Lipoproteins, Lipoproteins, LDL, Macrophages, Mice, Transgenic, Models, Biological, Mutation, Receptors, LDL, Recombinant Proteins, Triglycerides, Tumor Necrosis Factor-alpha, Amino Acid Substitution, Mice, Apolipoprotein B-100
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.